Australian Patent Office today accepted a patent for methods of synthesis for cannadibiol and analogues, and will begin a search of international patents to determine whether the process is a first.
Standardised pharmaceutical CBD is fast becoming the preferred option for medical applications, with doctors hesitant to recommend hemp products after federal regulators and consumer watchdogs reporting that pesticides and environmental toxins are often concentrated in CBD from hemp farms.
What caffeine is to mornings, CBD is rapidly becoming for evenings, the cleanest sedating social tonic de jour. CBD is not escaping the eye of the world’s most competitive beverage makers. Coca-Cola has run hot and cold on CBD, initially determined not to be left behind, and then throwing a damp cloth on speculation after legalities of CBD were questioned in Federal USA, so what is really going on?
The Pharmaceutical Grade CBD approved by the FDA and found in clinical trials to be effective against conditions such as epilepsy is “not the same” as marijuana products purchased from coffeeshop or cannabis stores.
That is the warning from Shlomo Shinnar, professor of neurology and epidemiology at the Albert Einstein College of Medicine and president of American Epilepsy Society
